HIMS250103C31000
- 0.01
- 0.000.00%
Hims & Hers Health Newsroom
Hims & Hers Health Options Spot-On: On January 17th, 102.64K Contracts Were Traded, With 520.85K Open Interest
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
Hims & Hers Health Down 3% After BoA Says Q4 Revenue Could Be a Miss
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $18
Cautious Outlook on Hims & Hers Health Amid Regulatory Risks and Revenue Concerns
Express News | U.S. FDA Chief Califf Says Current Regulations Not Enough To Protect Americans From Risks Of Compounded GLP-1 Drugs
Investors in Hims & Hers Health (NYSE:HIMS) Have Seen Enviable Returns of 440% Over the Past Three Years
10 Health Care Stocks With Whale Alerts In Today's Session
Hims & Hers in Focus as Eli Lilly GLP-1 Sales Disappoint
Needham's Top Stocks for 2025: AX, CYBR, CART and More
Morgan Stanley Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $42
Hims & Hers Health: Strong App Download Momentum and New Product Launches Drive Buy Recommendation
Hims & Hers Health Shares Fall After Downgrade From Citigroup
Express News | Watching Hims & Hers Health; Traders Circulate Popular Retail Trading Newsletter Saying Stock Is Poised For A Major Surge In 2025
HIMS Downgraded, Agilon Upgraded at Citi in 2025 Health Tech Review
Citi Downgrades Hims & Hers Health(HIMS.US) to Sell Rating, Raises Target Price to $25
What's Going On With Hims & Hers Health Stock?
Wall Street's Riskiest Stocks Are Melting Down as Retail Traders Face 'Day of Reckoning'
Here's Cedar Grove Capital Management's Investment Thesis for Hims & Hers Health (HIMS)
'Meta Ad Changes Threaten Telehealth's Weight Loss Boom' - The Information